Lilly, Chicago Bears' Cutler throw touchdowns for diabetes

Share this article:
Lilly, Chicago Bears' Cutler throw touchdowns for diabetes
Lilly, Chicago Bears' Cutler throw touchdowns for diabetes
Lilly extended its partnership with Chicago Bears quarterback Jay Cutler through a program that will provide $1,000 to the American Diabetes Association (ADA) for every touchdown pass Cutler completes this season.

Funds raised through the Touchdowns for Diabetes program will help send children with diabetes to ADA's summer camps. Tuition for a week at camp costs approximately $1,000 per child, according to a statement. For every completed pass that isn't a touchdown, Lilly will donate $100.

Scott MacGregor, senior communications associate at Lilly said the company would raise awareness for the program “through various means, including on the Bears Radio Network,” but declined to name any of the agencies involved.

The program's website will add video content in the coming weeks featuring Cutler talking about his own experiences with type 1 diabetes, according to MacGregor. Cutler has worked with Lilly, the ADA and the Juvenile Diabetes Research Foundation in the past, visiting children's hospitals and speaking with kids about the disease. MacGregor said those activities will continue during the off-season.

Cutler played for the Denver Broncos when he became an ambassador for Lilly's diabetes campaign last February, and was traded to the Bears in April.

Lilly diabetes products include Byetta, Humulin, Humalog and Glucagon.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...